Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

NCT02501473 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Follicular Low Grade Non-Hodgkin's Lymphoma

Interventions

DRUG: G100
DRUG: Pembrolizumab
DRUG: Rituximab

Sponsor

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Collaborators

[object Object]